85280-91-7

Basic information

• Product Name: (Z)-7-[(1R)-5α-Hydroxy-2β-[(E,S)-3-hydroxy-5-phenyl-1-pentenyl]-3-oxocyclopentan-1α-yl]-5-heptenoic acid
• Synonyms: (Z)-7-[(1R)-5α-Hydroxy-2β-[(E,S)-3-hydroxy-5-phenyl-1-pentenyl]-3-oxocyclopentan-1α-yl]-5-heptenoic acid;17-Phenyl-18,19,20-trinor-PGD2;17-phenyl-18,19,20-trinor-prostaglandin D2;OAQGPAZDRCBBLD-YTCWWFNZSA-N
• CAS NO: 85280-91-7
• Molecular Formula: C₂₃H₃₀O₅
• Molecular Weight: 386.4813
• Mol File: 85280-91-7.mol

Chemical Properties

• Boiling Point: 615.6°C at 760 mmHg
• Flash Point: 340.1°C
• Appearance: /
• Density: 1.215g/cm³
• Vapor Pressure: 5.18E-16mmHg at 25°C
• Refractive Index: 1.607
• CAS DataBase Reference: (Z)-7-[(1R)-5α-Hydroxy-2β-[(E,S)-3-hydroxy-5-phenyl-1-pentenyl]-3-oxocyclopentan-1α-yl]-5-heptenoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-7-[(1R)-5α-Hydroxy-2β-[(E,S)-3-hydroxy-5-phenyl-1-pentenyl]-3-oxocyclopentan-1α-yl]-5-heptenoic acid(85280-91-7)
• EPA Substance Registry System: (Z)-7-[(1R)-5α-Hydroxy-2β-[(E,S)-3-hydroxy-5-phenyl-1-pentenyl]-3-oxocyclopentan-1α-yl]-5-heptenoic acid(85280-91-7)

Safety Data

• Hazardous Substances Data: 85280-91-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(Z)-7-[(1R)-5α-Hydroxy-2β-[(E,S)-3-hydroxy-5-phenyl-1-pentenyl]-3-oxocyclopentan-1α-yl]-5-heptenoic acid is used as a pharmaceutical agent for its potential therapeutic effects. The specific stereochemistry and functional groups present in the molecule may contribute to its ability to modulate biological pathways and target specific receptors or enzymes, making it a candidate for the development of new drugs.
Used in Research Applications:
In the field of scientific research, (Z)-7-[(1R)-5α-Hydroxy-2β-[(E,S)-3-hydroxy-5-phenyl-1-pentenyl]-3-oxocyclopentan-1α-yl]-5-heptenoic acid can be used as a research tool to study the effects of its unique structure on biological systems. Researchers may investigate its interactions with various cellular targets, its potential as a modulator of specific signaling pathways, and its use in the development of new therapeutic strategies.
Used in Drug Development:
(Z)-7-[(1R)-5α-Hydroxy-2β-[(E,S)-3-hydroxy-5-phenyl-1-pentenyl]-3-oxocyclopentan-1α-yl]-5-heptenoic acid may also be utilized in drug development efforts, where its unique structure and functional groups can be further optimized to enhance its therapeutic potential. By understanding the molecular mechanisms underlying its biological activities, researchers can design and synthesize new analogs with improved efficacy and selectivity for specific medical applications.

InChI:InChI=1/C23H30O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,14-15,18-21,24-25H,2,7,10-13,16H2,(H,27,28)/b6-1-,15-14+/t18-,19+,20+,21-/m0/s1

Upstream product

• 62144-98-3 (5Z,13E)-(8R,9S,11R,12R,15S)-9,11-dihydroxy-17-phenyl-15-(tetrahydropyranyloxy)-18,19,20-trinorprostadienoic acid 
• 85235-30-9 (Z)-7-[(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-5-phenyl-3-(tetrahydro-pyran-2-yloxy)-pent-1-enyl]-5-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hept-5-enoic acid tetrahydro-pyran-2-yl ester 
• 85235-31-0 (Z)-7-[(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(E)-(S)-5-phenyl-3-(tetrahydro-pyran-2-yloxy)-pent-1-enyl]-5-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hept-5-enoic acid 
• 85235-24-1 (Z)-7-{(1R,2R,3R,5S)-3-(tert-Butyl-dimethyl-silanyloxy)-5-hydroxy-2-[(E)-(S)-5-phenyl-3-(tetrahydro-pyran-2-yloxy)-pent-1-enyl]-cyclopentyl}-hept-5-enoic acid 
• 85235-32-1 17-phenyl-18,19,20-trinor-PGF_2α 9,15-bis(tetrahydropyranyl ether) 
• 85235-23-0 (3aR,4R,5R,6aS)-5-(tert-Butyl-dimethyl-silanyloxy)-4-[(E)-(S)-5-phenyl-3-(tetrahydro-pyran-2-yloxy)-pent-1-enyl]-hexahydro-cyclopenta[b]furan-2-ol 
• 17814-85-6 (4-carboxybutyl)triphenylphosphonium bromide 
• 85235-33-2 (Z)-7-[(1R,2R,5S)-3-Oxo-2-[(E)-(S)-5-phenyl-3-(tetrahydro-pyran-2-yloxy)-pent-1-enyl]-5-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hept-5-enoic acid 

Relevant articles and documents

Synthesis and Platelet Aggregation Inhibiting Activity of Prostaglandin D Analogues

Several prostaglandin D (PGD) analogues have been synthesized, incorpotating the following variations: (a) varying degrees of side-chain unsaturation, (b) C-9 hydroxy removed or in the unnatural 9β configuration, (c) metabolically stabilized analogues (e.

Novel 11-oxoprostaglandin derivatives

11-Oxoprostaglandin derivatives of the formula STR1 wherein R2 is a hydrogen atom or alkyl of 1-5 carbon atoms, R3 is alkyl of 1-5 carbon atoms, alkylaryl, cycloalkyl of 5-6 ring carbon atoms and a total of 5-10 carbon atoms; benzodi